Compare
Allurion Technologies, Inc. vs Vivos Therapeutics, Inc. vs Nephros Inc vs Sonoma Pharmaceuticals, Inc.
| Latest fiscal year | Allurion Technologies, Inc. ALUR | Vivos Therapeutics, Inc. VVOS | Nephros Inc NEPH | Sonoma Pharmaceuticals, Inc. SNOA |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2026-03-31 |
| Revenue | $15.23M | $17.44M | $18.79M | $19.53M |
| Revenue growth (YoY) | -52.6% | +16.0% | +32.7% | +36.7% |
| Gross margin | 62.8% | 60.4% | 61.9% | 38.0% |
| Operating margin | -198.0% | -114.1% | 6.1% | -12.6% |
| Net margin | -188.8% | -121.4% | 6.4% | -16.3% |
| Net income | -$28.75M | -$21.17M | $1.19M | -$3.17M |
| EPS (Diluted) | -$3.81 | -$2.07 | $0.11 | -$1.89 |
| Operating cash flow | -$28.95M | -$15.26M | $1.60M | -$3.93M |
| Free cash flow | n/a | -$17.60M | n/a | -$4.12M |
| Cash & equivalents | $5.41M | $2.03M | $5.40M | $2.40M |
| Total assets | $15.77M | $25.15M | $13.64M | $13.96M |
| Total liabilities | $92.96M | $26.70M | $3.44M | $10.87M |
| Shareholders' equity | -$77.19M | -$1.49M | $10.20M | $3.10M |
| Return on year-end equity | n/a | n/a | 11.7% | -102.6% |
| Shares outstanding | 12.28M | 9.29M | 10.64M | 1.80M |
Revenue, most recent five fiscal years
| Fiscal year | Allurion Technologies, Inc. | Vivos Therapeutics, Inc. | Nephros Inc | Sonoma Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $15.23M Ended 2025-12-31 | $17.44M Ended 2025-12-31 | $18.79M Ended 2025-12-31 | $19.53M Ended 2026-03-31 |
| 1 year earlier | $32.11M Ended 2024-12-31 | $15.03M Ended 2024-12-31 | $14.16M Ended 2024-12-31 | $14.29M Ended 2025-03-31 |
| 2 years earlier | $53.47M Ended 2023-12-31 | $13.80M Ended 2023-12-31 | $14.24M Ended 2023-12-31 | $12.73M Ended 2024-03-31 |
| 3 years earlier | $64.21M Ended 2022-12-31 | $16.02M Ended 2022-12-31 | $9.97M Ended 2022-12-31 | $13.27M Ended 2023-03-31 |
| 4 years earlier | n/a | $16.89M Ended 2021-12-31 | $10.22M Ended 2021-12-31 | $12.63M Ended 2022-03-31 |